Drugmaker Gilead Says 5-Day Course Of Remdesivir Helps
DRUGMAKER GILEAD SCIENCES SAYS A STUDY SHOWED THE ANTIVIRAL DRUG REMDESIVIR CAN HELP PATIENTS WITH MODERATE COVID-19 PNEUMONIA RECOVER; A 5-DAY DOSE SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT BUT A 10-DAY DOSE DID NOT
(CNN) – Drugmaker Gilead sciences says a study shows the antiviral drug Remdesivir can help patients with moderate COVID-19 pneumonia recover.
A study of 600 patients found those given a five-day course of the drug were 65% more likely to see clinical improvement after 11 days, compared to those given the standard of care.
Those given a 10-day treatment of the drug also showed an improvement, but it was not statistically significant.
The results have not yet been published in a peer-reviewed medical journal.
Gilead says in the coming weeks it plans to submit the full data for publication.